Big Pharma's Next Partner In China: Diagnostics
This article was originally published in PharmAsia News
China offers a fertile ground for combing pharma with diagnostics as it looks to cut cost and improve healthcare results, but a lack of quality and core technologies will mean many diagnostic startups will be forced out in the next wave of consolidation. Pharmas will have to partner selectively and navigate carefully, top executives say in a recent forum.
Register for our free email digests: